| Stereochemistry | ABSOLUTE |
| Molecular Formula | C32H38F2N2O5S2 |
| Molecular Weight | 632.781 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(C1CCN(CC[C@H](C2=CC=C(C=C2)S(C)(=O)=O)C3=CC(F)=CC(F)=C3)CC1)C(=O)CC4=CC=C(C=C4)S(C)(=O)=O
InChI
InChIKey=SCXSQUUTGCWHFU-WJOKGBTCSA-N
InChI=1S/C32H38F2N2O5S2/c1-4-36(32(37)19-23-5-9-29(10-6-23)42(2,38)39)28-13-16-35(17-14-28)18-15-31(25-20-26(33)22-27(34)21-25)24-7-11-30(12-8-24)43(3,40)41/h5-12,20-22,28,31H,4,13-19H2,1-3H3/t31-/m1/s1
| Molecular Formula | C32H38F2N2O5S2 |
| Molecular Weight | 632.781 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
AZD5672 was developed by AstraZeneca for the treatment of rheumatoid arthritis. It was found that the drug inhibits P-glycoprotein and is a CCR5 antagonist. Exists hypothesis that inhibition of CCR5 can bring benefits in the treatment of rheumatoid arthritis. In July 2009, Phase-II for Rheumatoid arthritis was discontinued.
